FibroGen, Inc. Announces Full Exercise Of Greenshoe Option

SAN FRANCISCO--(BUSINESS WIRE)--FibroGen, Inc. (NASDAQ:FGEN), a research-based biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics to treat serious unmet medical needs, today announced that the underwriters of its initial public offering exercised in full their option to purchase an additional 1,215,000 shares of common stock from FibroGen at the initial public offering price of $18.00 per share, less the underwriting discount. With this exercise, the initial public offering totals 9,315,000 shares of common stock of FibroGen, representing gross proceeds of approximately $167.7 million, prior to deducting the underwriting discount and estimated offering expenses.